Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ICP-248 + orelabrutinib vs pirtobrutinib in relapsed/refractory mantle cell lymphoma
CTR20263184Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mesutoclax in mantle cell lymphoma (MCL), sponsored by Innovent Biologics. Started Aug 2026; status: active.
02
Drugs
mesutoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20263184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263184.